Fixed drug eruption: 7 case reportsIn a study, 7 patients aged 35-77 years (4 women and 3 men) were described, who developed fixed drug eruption during nonsteroidal anti-inflammatory therapy with etoricoxib [duration of treatments to reactions onset, routes and dosages not stated].Patient 1: A 35-year-old woman, started receiving etoricoxib with concomitant administration of ibuprofen and ketoprofen. Subsequently, she developed 2 episodes of fixed drug eruption with multilocular involvement in upper eyelids, flanks, axillae and a bullous lesion in the left groin. After resolution, she had residual hyperpigmented lesion in the involved site. She underwent a patch test on the residual hyperpigmented lesion with etoricoxib using crushed tablets in petrolatum. Additionally, she had patch test for ibuprofen and ketoprofen. The results for etoricoxib patch test was positive, while for ibuprofen and ketoprofen were negative. She showed oral tolerance to ibuprofen and ketoprofen.Patient 2: A 56-year-old man, started receiving etoricoxib with concomitant administration of paracetamol. Subsequently, he developed 3 episodes of fixed drug eruption with multilocular vesiculobullous lesions on the right cheek, both thumbs, anterior neck, ankles, back and groin. After resolution, he had residual hyperpigmented lesion in the involved site. He underwent a patch test on the residual hyperpigmented lesion with etoricoxib using crushed tablets in petrolatum. Additionally, he had patch test for paracetamol. The results for etoricoxib patch test was positive, while for paracetamol was negative. He showed oral tolerance to paracetamol.Patient 3: A 77-year-old woman, started receiving etoricoxib. Subsequently, she developed 2 episodes of fixed drug eruption with erythematous macules on the neck and cheek. After resolution, she had residual hyperpigmented lesion in the involved site. She underwent a patch test on the residual hyperpigmented lesion with etoricoxib using crushed tablets in petrolatum. The results for etoricoxib patch test was positive.Patient 4: A 75-year-old man, started receiving etoricoxib with concomitant administration of dipyrone [metamizole]. Subsequently, he developed 3 episodes of fixed drug eruption with pigmented macules on the back (left scapula and lumbar area). After resolution, he had residual hyperpigmented lesion in the involved site. He underwent a patch test on the residual hyperpigmented lesion with etoricoxib using crushed tablets in petrolatum. Additionally, he had patch test for dipyrone. The results for etoricoxib patch test was positive, while for dipyrone was negative. He showed oral tolerance to dipyrone.Patient 5: A 64-year-old woman, started receiving etoricoxib with concomitant administration of naproxen and paracetamol. Subsequently, she developed 2 episodes of fixed drug eruption with erythematous macules on forearms and neckline area. After resolution, she had residual hyperpigmented lesion in the involved site. She underwent a patch test on the residual hyperpigmented lesion with etoricoxi...